Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker

Background. Gangliosides act as important roles in tumor progression. B4GALNT1 is a key enzyme in ganglioside biosynthesis. B4GALNT1 expression is linked to tumorigenesis and the prognosis of tumor patients. Nevertheless, the role of B4GALNT1 in pan-cancer remains unclear. Methods. Several databases...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2022-07, Vol.2022, p.1-28
Main Authors: Yi, Hang, Lin, Yiwen, Li, Yutong, Guo, Yeqi, Yuan, Ligong, Mao, Yousheng
Format: Article
Language:English
Subjects:
Biomarkers
Biosynthesis
Cancer
Correlation analysis
DNA methylation
Enzymes
Epigenetics
Fibroblasts
Gangliosides
Gene expression
Human papillomavirus
Immunology
Medical prognosis
Metastases
Mutation
Patients
Prognosis
Sensitivity analysis
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3
cites cdi_FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3
container_end_page 28
container_issue
container_start_page 1
container_title Journal of immunology research
container_volume 2022
creator Yi, Hang
Lin, Yiwen
Li, Yutong
Guo, Yeqi
Yuan, Ligong
Mao, Yousheng
description Background. Gangliosides act as important roles in tumor progression. B4GALNT1 is a key enzyme in ganglioside biosynthesis. B4GALNT1 expression is linked to tumorigenesis and the prognosis of tumor patients. Nevertheless, the role of B4GALNT1 in pan-cancer remains unclear. Methods. Several databases, including TCGA, GEO, GTEx, NCI-60, and TIMER, were searched. Methods including correlation analysis, Cox regression analysis, and Kaplan-Meier analysis were used to explore the expression pattern, prognosis, tumor infiltration pattern, genetics and epigenetics, and drug sensitivity of B4GALNT1 in pan-cancer patients from the above datasets. Results. B4GALNT1 was found to be aberrantly expressed in multiple types of tumors. The survival status of tumor patients was significantly related to B4GALNT1 expression, but the correlations were tumor-specific. Moreover, the expression of B4GALNT1 was associated with ImmuneScore and StromalScore in 21 and 27 tumor types, respectively. Also, B4GALNT1 was significantly associated with TMB, MSI, MMR, and DNA methylation. Additionally, the sensitivity of 9 drugs was correlated with the expression of B4GALNT1. Conclusion. A correlation of B4GALNT1 expression with prognosis exists in multiple types of cancers. In addition, B4GALNT1 expression may play a role in TME and tumor immunity regulation. Further investigation of the biological mechanisms of its different roles in tumorigenesis and clinical application as a biomarker is still required.
doi_str_mv 10.1155/2022/4355890
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3180ab48411349cab5ff47dcac694f93</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3180ab48411349cab5ff47dcac694f93</doaj_id><sourcerecordid>2699543410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3</originalsourceid><addsrcrecordid>eNp9kUtv1DAURi0EolXpjh8QiQ0ShMavxN4gTUe0jDSCWbRr68aPqUtiFzsB9d_XQ0ZIZcHKlu_x8ed7EXqLm08Yc35BGkIuGOVcyOYFOiUUs7rDvH153AvR4hN0nrPvG950lLaifY1OKJeHO_wU3e4g1GsI2qZqFWB4zD5X0VWX7Hq1_XaDK8gVVLs42TB5GKpdivsQ8-R1BcFUm3GcQxzi3utSvPRxhPTDpjfolYMh2_PjeoZur77crL_W2-_Xm_VqW-sSeKoBKAfLO4wFd9QRYkAzzlrtQHe8kVYAM5IaK4zEGBvRGyJoT3ohHGuZpWdos3hNhHv1kHx5_lFF8OrPQUx7BalkHayiWDTQM8Ewpkxq6LlzrDMadCuZk7S4Pi-uh7kfrdHlwwmGZ9LnleDv1D7-UqWVhHW8CN4fBSn-nG2e1OiztsMAwcY5K9JKKXkJ0BT03T_ofZxTaf9CcUYX6uNC6RRzTtb9DYMbdRi_OoxfHcdf8A8LfueDgd_-__QTUSmsJg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699543410</pqid></control><display><type>article</type><title>Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Yi, Hang ; Lin, Yiwen ; Li, Yutong ; Guo, Yeqi ; Yuan, Ligong ; Mao, Yousheng</creator><contributor>Zhan, Cheng ; Cheng Zhan</contributor><creatorcontrib>Yi, Hang ; Lin, Yiwen ; Li, Yutong ; Guo, Yeqi ; Yuan, Ligong ; Mao, Yousheng ; Zhan, Cheng ; Cheng Zhan</creatorcontrib><description>Background. Gangliosides act as important roles in tumor progression. B4GALNT1 is a key enzyme in ganglioside biosynthesis. B4GALNT1 expression is linked to tumorigenesis and the prognosis of tumor patients. Nevertheless, the role of B4GALNT1 in pan-cancer remains unclear. Methods. Several databases, including TCGA, GEO, GTEx, NCI-60, and TIMER, were searched. Methods including correlation analysis, Cox regression analysis, and Kaplan-Meier analysis were used to explore the expression pattern, prognosis, tumor infiltration pattern, genetics and epigenetics, and drug sensitivity of B4GALNT1 in pan-cancer patients from the above datasets. Results. B4GALNT1 was found to be aberrantly expressed in multiple types of tumors. The survival status of tumor patients was significantly related to B4GALNT1 expression, but the correlations were tumor-specific. Moreover, the expression of B4GALNT1 was associated with ImmuneScore and StromalScore in 21 and 27 tumor types, respectively. Also, B4GALNT1 was significantly associated with TMB, MSI, MMR, and DNA methylation. Additionally, the sensitivity of 9 drugs was correlated with the expression of B4GALNT1. Conclusion. A correlation of B4GALNT1 expression with prognosis exists in multiple types of cancers. In addition, B4GALNT1 expression may play a role in TME and tumor immunity regulation. Further investigation of the biological mechanisms of its different roles in tumorigenesis and clinical application as a biomarker is still required.</description><identifier>ISSN: 2314-8861</identifier><identifier>EISSN: 2314-7156</identifier><identifier>DOI: 10.1155/2022/4355890</identifier><identifier>PMID: 35935585</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Biomarkers ; Biosynthesis ; Cancer ; Correlation analysis ; DNA methylation ; Enzymes ; Epigenetics ; Fibroblasts ; Gangliosides ; Gene expression ; Human papillomavirus ; Immunology ; Medical prognosis ; Metastases ; Mutation ; Patients ; Prognosis ; Sensitivity analysis ; Tumorigenesis ; Tumors</subject><ispartof>Journal of immunology research, 2022-07, Vol.2022, p.1-28</ispartof><rights>Copyright © 2022 Hang Yi et al.</rights><rights>Copyright © 2022 Hang Yi et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Hang Yi et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3</citedby><cites>FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3</cites><orcidid>0000-0003-1120-241X ; 0000-0002-0564-4767 ; 0000-0002-8521-7422</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2699543410/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2699543410?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><contributor>Zhan, Cheng</contributor><contributor>Cheng Zhan</contributor><creatorcontrib>Yi, Hang</creatorcontrib><creatorcontrib>Lin, Yiwen</creatorcontrib><creatorcontrib>Li, Yutong</creatorcontrib><creatorcontrib>Guo, Yeqi</creatorcontrib><creatorcontrib>Yuan, Ligong</creatorcontrib><creatorcontrib>Mao, Yousheng</creatorcontrib><title>Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker</title><title>Journal of immunology research</title><description>Background. Gangliosides act as important roles in tumor progression. B4GALNT1 is a key enzyme in ganglioside biosynthesis. B4GALNT1 expression is linked to tumorigenesis and the prognosis of tumor patients. Nevertheless, the role of B4GALNT1 in pan-cancer remains unclear. Methods. Several databases, including TCGA, GEO, GTEx, NCI-60, and TIMER, were searched. Methods including correlation analysis, Cox regression analysis, and Kaplan-Meier analysis were used to explore the expression pattern, prognosis, tumor infiltration pattern, genetics and epigenetics, and drug sensitivity of B4GALNT1 in pan-cancer patients from the above datasets. Results. B4GALNT1 was found to be aberrantly expressed in multiple types of tumors. The survival status of tumor patients was significantly related to B4GALNT1 expression, but the correlations were tumor-specific. Moreover, the expression of B4GALNT1 was associated with ImmuneScore and StromalScore in 21 and 27 tumor types, respectively. Also, B4GALNT1 was significantly associated with TMB, MSI, MMR, and DNA methylation. Additionally, the sensitivity of 9 drugs was correlated with the expression of B4GALNT1. Conclusion. A correlation of B4GALNT1 expression with prognosis exists in multiple types of cancers. In addition, B4GALNT1 expression may play a role in TME and tumor immunity regulation. Further investigation of the biological mechanisms of its different roles in tumorigenesis and clinical application as a biomarker is still required.</description><subject>Biomarkers</subject><subject>Biosynthesis</subject><subject>Cancer</subject><subject>Correlation analysis</subject><subject>DNA methylation</subject><subject>Enzymes</subject><subject>Epigenetics</subject><subject>Fibroblasts</subject><subject>Gangliosides</subject><subject>Gene expression</subject><subject>Human papillomavirus</subject><subject>Immunology</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Mutation</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Sensitivity analysis</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>2314-8861</issn><issn>2314-7156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUtv1DAURi0EolXpjh8QiQ0ShMavxN4gTUe0jDSCWbRr68aPqUtiFzsB9d_XQ0ZIZcHKlu_x8ed7EXqLm08Yc35BGkIuGOVcyOYFOiUUs7rDvH153AvR4hN0nrPvG950lLaifY1OKJeHO_wU3e4g1GsI2qZqFWB4zD5X0VWX7Hq1_XaDK8gVVLs42TB5GKpdivsQ8-R1BcFUm3GcQxzi3utSvPRxhPTDpjfolYMh2_PjeoZur77crL_W2-_Xm_VqW-sSeKoBKAfLO4wFd9QRYkAzzlrtQHe8kVYAM5IaK4zEGBvRGyJoT3ohHGuZpWdos3hNhHv1kHx5_lFF8OrPQUx7BalkHayiWDTQM8Ewpkxq6LlzrDMadCuZk7S4Pi-uh7kfrdHlwwmGZ9LnleDv1D7-UqWVhHW8CN4fBSn-nG2e1OiztsMAwcY5K9JKKXkJ0BT03T_ofZxTaf9CcUYX6uNC6RRzTtb9DYMbdRi_OoxfHcdf8A8LfueDgd_-__QTUSmsJg</recordid><startdate>20220728</startdate><enddate>20220728</enddate><creator>Yi, Hang</creator><creator>Lin, Yiwen</creator><creator>Li, Yutong</creator><creator>Guo, Yeqi</creator><creator>Yuan, Ligong</creator><creator>Mao, Yousheng</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1120-241X</orcidid><orcidid>https://orcid.org/0000-0002-0564-4767</orcidid><orcidid>https://orcid.org/0000-0002-8521-7422</orcidid></search><sort><creationdate>20220728</creationdate><title>Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker</title><author>Yi, Hang ; Lin, Yiwen ; Li, Yutong ; Guo, Yeqi ; Yuan, Ligong ; Mao, Yousheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Biosynthesis</topic><topic>Cancer</topic><topic>Correlation analysis</topic><topic>DNA methylation</topic><topic>Enzymes</topic><topic>Epigenetics</topic><topic>Fibroblasts</topic><topic>Gangliosides</topic><topic>Gene expression</topic><topic>Human papillomavirus</topic><topic>Immunology</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Mutation</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Sensitivity analysis</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi, Hang</creatorcontrib><creatorcontrib>Lin, Yiwen</creatorcontrib><creatorcontrib>Li, Yutong</creatorcontrib><creatorcontrib>Guo, Yeqi</creatorcontrib><creatorcontrib>Yuan, Ligong</creatorcontrib><creatorcontrib>Mao, Yousheng</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of immunology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi, Hang</au><au>Lin, Yiwen</au><au>Li, Yutong</au><au>Guo, Yeqi</au><au>Yuan, Ligong</au><au>Mao, Yousheng</au><au>Zhan, Cheng</au><au>Cheng Zhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker</atitle><jtitle>Journal of immunology research</jtitle><date>2022-07-28</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>28</epage><pages>1-28</pages><issn>2314-8861</issn><eissn>2314-7156</eissn><abstract>Background. Gangliosides act as important roles in tumor progression. B4GALNT1 is a key enzyme in ganglioside biosynthesis. B4GALNT1 expression is linked to tumorigenesis and the prognosis of tumor patients. Nevertheless, the role of B4GALNT1 in pan-cancer remains unclear. Methods. Several databases, including TCGA, GEO, GTEx, NCI-60, and TIMER, were searched. Methods including correlation analysis, Cox regression analysis, and Kaplan-Meier analysis were used to explore the expression pattern, prognosis, tumor infiltration pattern, genetics and epigenetics, and drug sensitivity of B4GALNT1 in pan-cancer patients from the above datasets. Results. B4GALNT1 was found to be aberrantly expressed in multiple types of tumors. The survival status of tumor patients was significantly related to B4GALNT1 expression, but the correlations were tumor-specific. Moreover, the expression of B4GALNT1 was associated with ImmuneScore and StromalScore in 21 and 27 tumor types, respectively. Also, B4GALNT1 was significantly associated with TMB, MSI, MMR, and DNA methylation. Additionally, the sensitivity of 9 drugs was correlated with the expression of B4GALNT1. Conclusion. A correlation of B4GALNT1 expression with prognosis exists in multiple types of cancers. In addition, B4GALNT1 expression may play a role in TME and tumor immunity regulation. Further investigation of the biological mechanisms of its different roles in tumorigenesis and clinical application as a biomarker is still required.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>35935585</pmid><doi>10.1155/2022/4355890</doi><tpages>28</tpages><orcidid>https://orcid.org/0000-0003-1120-241X</orcidid><orcidid>https://orcid.org/0000-0002-0564-4767</orcidid><orcidid>https://orcid.org/0000-0002-8521-7422</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-8861
ispartof Journal of immunology research, 2022-07, Vol.2022, p.1-28
issn 2314-8861
2314-7156
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3180ab48411349cab5ff47dcac694f93
source Publicly Available Content Database; Wiley Open Access; PubMed Central
subjects Biomarkers
Biosynthesis
Cancer
Correlation analysis
DNA methylation
Enzymes
Epigenetics
Fibroblasts
Gangliosides
Gene expression
Human papillomavirus
Immunology
Medical prognosis
Metastases
Mutation
Patients
Prognosis
Sensitivity analysis
Tumorigenesis
Tumors
title Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A41%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pan-Cancer%20Analysis%20of%20B4GALNT1%20as%20a%20Potential%20Prognostic%20and%20Immunological%20Biomarker&rft.jtitle=Journal%20of%20immunology%20research&rft.au=Yi,%20Hang&rft.date=2022-07-28&rft.volume=2022&rft.spage=1&rft.epage=28&rft.pages=1-28&rft.issn=2314-8861&rft.eissn=2314-7156&rft_id=info:doi/10.1155/2022/4355890&rft_dat=%3Cproquest_doaj_%3E2699543410%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c589t-aa35ae571185f3f22dac4546cfac7509e8a4d93de8d9111d8bd283b2b88f464e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2699543410&rft_id=info:pmid/35935585&rfr_iscdi=true